{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,11]],"date-time":"2026-04-11T01:52:08Z","timestamp":1775872328418,"version":"3.50.1"},"reference-count":20,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,3,2]],"date-time":"2026-03-02T00:00:00Z","timestamp":1772409600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Immune checkpoint inhibitors (ICIs) can trigger immune-related adverse events (irAEs), among which Stevens\u2013Johnson syndrome\/toxic epidermal necrolysis (SJS\/TEN) is exceptionally rare but potentially fatal. Sintilimab, a PD-1 inhibitor increasingly used for advanced gastric cancer, has only sporadically been linked to SJS\/TEN.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Case presentation<\/jats:title>\n                    <jats:p>We report a 60-year-old man with metastatic gastric adenocarcinoma who developed TEN 7 days after the first sintilimab infusion. He presented with rapidly progressive diffuse erythema, bullae, and epidermal detachment involving &amp;gt;90% of the body surface area, accompanied by fever and upper gastrointestinal bleeding leading to hemodynamic instability.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Interventions<\/jats:title>\n                    <jats:p>Sintilimab was permanently discontinued. Multidisciplinary management was initiated, including intensive fluid and electrolyte resuscitation, high-dose intravenous immunoglobulin, systemic corticosteroids with careful bleeding surveillance, specialized burn-type wound care, tailored anti-infective therapy based on susceptibility testing, and aggressive nutritional support. This case report was prepared in accordance with the CARE (CAse REport) guidelines.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Outcomes<\/jats:title>\n                    <jats:p>Skin lesions gradually re-epithelialized, infection was controlled, and gastrointestinal bleeding stabilized. The patient fully recovered from TEN and was discharged on hospital day 32. No recurrence or secondary infection was observed on follow-up.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Although effective for gastric cancer, sintilimab may rarely induce life-threatening TEN. Early recognition, immediate ICI withdrawal, and coordinated multidisciplinary care are pivotal to survival. This case highlights the importance of early recognition, immediate discontinuation of ICIs, and coordinated multidisciplinary management in patients who develop life-threatening cutaneous immune-related adverse events.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fimmu.2026.1771194","type":"journal-article","created":{"date-parts":[[2026,3,2]],"date-time":"2026-03-02T15:29:31Z","timestamp":1772465371000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Sintilimab-induced toxic epidermal necrolysis complicated in advanced gastric cancer: a case report and literature review"],"prefix":"10.3389","volume":"17","author":[{"given":"Qi","family":"Zhao","sequence":"first","affiliation":[{"name":"Cancer Center, Yantai Affiliated Hospital of Binzhou Medical University, The Medical College of Binzhou Medical University","place":["Yantai, China"]},{"name":"Hainan Academy of Medical Sciences, Hainan Medical University","place":["Haikou, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rui-Ke","family":"Cao","sequence":"additional","affiliation":[{"name":"Department of Medical Aesthetics, Burns and Plastic Surgery, Yantai Affiliated Hospital of Binzhou Medical University, The Medical College of Binzhou Medical University","place":["Yantai, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hai-Peng","family":"Zou","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Yantai Affiliated Hospital of Binzhou Medical University, The Medical College of Binzhou Medical University","place":["Yantai, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rui-Bin","family":"Wang","sequence":"additional","affiliation":[{"name":"Cancer Center, Yantai Affiliated Hospital of Binzhou Medical University, The Medical College of Binzhou Medical University","place":["Yantai, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ling-Xia","family":"Yu","sequence":"additional","affiliation":[{"name":"Cancer Center, Yantai Affiliated Hospital of Binzhou Medical University, The Medical College of Binzhou Medical University","place":["Yantai, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei","family":"Zhang","sequence":"additional","affiliation":[{"name":"Cancer Center, Yantai Affiliated Hospital of Binzhou Medical University, The Medical College of Binzhou Medical University","place":["Yantai, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Li-Na","family":"Wang","sequence":"additional","affiliation":[{"name":"Cancer Center, Yantai Affiliated Hospital of Binzhou Medical University, The Medical College of Binzhou Medical University","place":["Yantai, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yan-Dong","family":"Miao","sequence":"additional","affiliation":[{"name":"Cancer Center, Yantai Affiliated Hospital of Binzhou Medical University, The Medical College of Binzhou Medical University","place":["Yantai, China"]},{"name":"Guangdong Provincial Key Laboratory of Medical Biomechanics, National Key Discipline of Human Anatomy, School of Basic Medical Sciences, Southern Medical University","place":["Guangzhou, China"]},{"name":"Department of Oncology, Xinhui District People\u2019s Hospital","place":["Jiangmen, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2026,3,2]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2018.3923","article-title":"Fatal toxic effects associated with immune checkpoint inhibitors: A systematic review and meta-analysis","volume":"4","author":"Wang","year":"2018","journal-title":"JAMA Oncol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.7150\/ijbs.89376","article-title":"Uncovering the flip side of immune checkpoint inhibitors: a comprehensive review of immune-related adverse events and predictive biomarkers","volume":"20","author":"Miao","year":"2024","journal-title":"Int J Biol Sci"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2025.03.106","article-title":"Stevens-Johnson syndrome and toxic epidermal necrolysis associated with the use of immune checkpoint inhibitors: A disproportionality analysis using the Food and Drug Administration adverse event reporting system database","volume":"93","author":"Pathak","year":"2025","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"B4","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/S0140-6736(21)00797-2","article-title":"First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial","volume":"398","author":"Janjigian","year":"2021","journal-title":"Lancet (London England)"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2023.19918","article-title":"Sintilimab plus chemotherapy for unresectable gastric or gastroesophageal junction cancer: the ORIENT-16 randomized clinical trial","volume":"330","author":"Xu","year":"2023","journal-title":"Jama"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2024.06.066","article-title":"Retrospective cohort study characterizing PD-1\/PD-L1 checkpoint inhibition associated Stevens-Johnson syndrome and toxic epidermal necrolysis","volume":"91","author":"Chen","year":"2024","journal-title":"J Am Acad Dermatol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1001\/archderm.1993.01680220104023","article-title":"Clinical classification of cases of toxic epidermal necrolysis, Stevens-Johnson syndrome, and erythema multiforme","volume":"129","author":"Bastuji-Garin","year":"1993","journal-title":"Arch Dermatol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2025.1568316","article-title":"Stevens-Johnson syndrome induced by Sintilimab: a case report and literature review","volume":"15","author":"Kuang","year":"2025","journal-title":"Front Oncol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.1065137","article-title":"Case Report: Toxic epidermal necrolysis associated with sintilimab in a patient with relapsed thymic carcinoma","volume":"12","author":"Yang","year":"2022","journal-title":"Front Oncol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.14740\/jmc3992","article-title":"Steven-johnson syndrome: A rare but serious adverse event of nivolumab use in a patient with metastatic gastric adenocarcinoma","volume":"13","author":"Saad","year":"2022","journal-title":"J Med cases"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1414136","article-title":"Stevens-Johnson syndrome and toxic epidermal necrolysis associated with immune checkpoint inhibitors: a systematic review","volume":"15","author":"Zhou","year":"2024","journal-title":"Front Immunol"},{"key":"B12","doi-asserted-by":"publisher","first-page":"bcr2013201554","DOI":"10.1136\/bcr-2013-201554","article-title":"The CARE guidelines: consensus-based clinical case reporting guideline development","volume":"2013","author":"Gagnier","year":"2013","journal-title":"BMJ Case Rep"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1046\/j.1523-1747.2000.00061.x","article-title":"SCORTEN: a severity-of-illness score for toxic epidermal necrolysis","volume":"115","author":"Bastuji-Garin","year":"2000","journal-title":"J Invest Dermatol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.2147\/ccid.S401286","article-title":"Adalimumab for sintilimab-induced toxic epidermal necrolysis in a patient with metastatic gastric Malignancy: A case report and literature review","volume":"16","author":"Zhang","year":"2023","journal-title":"Clinical cosmetic investigational Dermatol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.2169\/internalmedicine.4701-20","article-title":"Sj\u00f6gren\u2019s syndrome as an immune-related adverse event of nivolumab treatment for gastric cancer","volume":"59","author":"Higashi","year":"2020","journal-title":"Internal Med (Tokyo Japan)"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.2217\/imt-2023-0081","article-title":"Lichenoid dermatitis following PD-1 inhibitor-induced toxic epidermal necrolysis: a case report and literature review","volume":"15","author":"Zhang","year":"2023","journal-title":"Immunotherapy"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1007\/s10787-024-01590-0","article-title":"Cyclosporin for the treatment of Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN): a systematic review of observational studies and clinical trials focusing on single therapy, combination therapy, and comparative assessments","volume":"33","author":"Nazerian","year":"2025","journal-title":"Inflammopharmacology"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.01440","article-title":"Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: ASCO guideline update","volume":"39","author":"Schneider","year":"2021","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"B19","doi-asserted-by":"publisher","first-page":"101290","DOI":"10.1016\/j.gore.2023.101290","article-title":"SJS\/TEN immune-related dermatologic reaction secondary to immune checkpoint inhibitor pembrolizumab in skin of color","volume":"50","author":"Pierre","year":"2023","journal-title":"Gynecologic Oncol Rep"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.14530","article-title":"U.K. guidelines for the management of Stevens-Johnson syndrome\/toxic epidermal necrolysis in adults 2016","volume":"174","author":"Creamer","year":"2016","journal-title":"Br J Dermatol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1771194\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,2]],"date-time":"2026-03-02T15:29:32Z","timestamp":1772465372000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1771194\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,2]]},"references-count":20,"alternative-id":["10.3389\/fimmu.2026.1771194"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1771194","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,2]]},"article-number":"1771194"}}